

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

### **CHANGE OF NON-EXECUTIVE DIRECTOR**

The Board announces that (i) Mr. Huang Liming has been appointed as a non-executive director of the Company, and (ii) Dr. Lyu Dong has resigned as a non-executive director of the Company, in both case with effect from 10 March 2025.

#### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”) announces that Mr. Huang Liming (“**Mr. Huang**”) has been appointed as a non-executive director of the Company with effect from 10 March 2025.

Mr. Huang, aged 47, is a partner at Hillhouse Investment Management, Ltd. (“**Hillhouse**”). Prior to joining Hillhouse in July 2017, he was a managing director of ICBC Tianjin Advisory LLP (天津工銀國際投資顧問合夥企業(有限合夥)) from April 2011 to June 2017. From June 2010 to March 2011, he served as an executive director of J.P. Morgan Securities (Asia Pacific) Limited. Before that, Mr. Huang served as a vice president of Affinity Equity Partners between March 2009 to May 2010. Mr. Huang worked as an associate in the investment banking department at Goldman Sachs (Asia) L.L.C. and later held the position of executive director of the Asia Special Situation Group from July 2003 to February 2009. Mr. Huang received his bachelor’s degree in Economics and his master’s degree in Economics from Fudan University (復旦大學) in the PRC in July 1999 and July 2002 respectively.

As at the date of the announcement, Hillhouse NEV Holdings Limited holds 552,324,108 shares of the Company, representing approximately 14.68% of the issued share capital of the Company, and hence is a substantial shareholder of the Company. Hillhouse NEV Holdings Limited is wholly-owned by Hillhouse Fund V, L.P. and Hillhouse is the sole investment manager of Hillhouse NEV Holdings Limited.

Save as disclosed in this announcement, Mr. Huang (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) does not have and is not deemed to have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) does not hold any other positions in the Company and its subsidiaries. Save as disclosed in the announcement, there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Huang that need to be brought to the attention of the shareholders of the Company.

Pursuant to the Company's Bye-Laws, Mr. Huang is subject to retirement and is eligible for re-election at the forthcoming annual general meeting of the Company. Subject to Mr. Huang being re-elected as a non-executive director of the Company at the forthcoming annual general meeting of the Company, Mr. Huang will hold office for an initial term of two years commencing 10 March 2025. During Mr. Huang's tenure, his appointment may be terminated by either party giving the other not less than one month's notice in writing. Mr. Huang will not be paid any director fees.

The Board would like to extend its welcome to Mr. Huang for joining the Board.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board further announces that Dr. Lyu Dong ("**Dr. Lyu**") has resigned as a non-executive director of the Company with effect from 10 March 2025 due to other work commitments.

Dr. Lyu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Dr. Lyu for his valuable contributions to the Company during his tenure of office.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 10 March 2025

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.*